Stefani Spranger

Stefani Spranger

Howard S. and Linda B. Stern Career Development Professor

Stefani Spranger studies how the body’s immune system interacts with growing tumors to harness the immune response to fight cancer.





Paul Thompson



Assistant Phone


  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.


  • Forbeck Fellow, 2015

Recent Publications

  1. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. Bao, R, Spranger, S, Hernandez, K, Zha, Y, Pytel, P, Luke, JJ, Gajewski, TF, Volchenboum, SL, Cohn, SL, Desai, AV et al.. 2021. J Immunother Cancer 9, .
    doi: 10.1136/jitc-2021-002417PMID:34272305
  2. Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Luengo, A, Li, Z, Gui, DY, Sullivan, LB, Zagorulya, M, Do, BT, Ferreira, R, Naamati, A, Ali, A, Lewis, CA et al.. 2021. Mol Cell 81, 691-707.e6.
    doi: 10.1016/j.molcel.2020.12.012PMID:33382985
  3. Direct and Indirect Regulators of Epithelial-Mesenchymal Transition-Mediated Immunosuppression in Breast Carcinomas. Dongre, A, Rashidian, M, Eaton, EN, Reinhardt, F, Thiru, P, Zagorulya, M, Nepal, S, Banaz, T, Martner, A, Spranger, S et al.. 2021. Cancer Discov 11, 1286-1305.
    doi: 10.1158/2159-8290.CD-20-0603PMID:33328216
  4. Frontiers in cancer immunotherapy-a symposium report. Cable, J, Greenbaum, B, Pe'er, D, Bollard, CM, Bruni, S, Griffin, ME, Allison, JP, Wu, CJ, Subudhi, SK, Mardis, ER et al.. 2021. Ann N Y Acad Sci 1489, 30-47.
    doi: 10.1111/nyas.14526PMID:33184911
  5. Impact of anatomic site on antigen-presenting cells in cancer. Zagorulya, M, Duong, E, Spranger, S. 2020. J Immunother Cancer 8, .
    doi: 10.1136/jitc-2020-001204PMID:33020244
  6. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. Ascierto, PA, Fox, BA, Urba, WJ, Anderson, AC, Atkins, MB, Borden, EC, Brahmer, JR, Butterfield, LH, Cesano, A, Chen, DC et al.. 2020. J Immunother Cancer 8, .
    doi: 10.1136/jitc-2020-000878PMID:32300051
  7. Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cohen, MA, Zhang, S, Sengupta, S, Ma, H, Bell, GW, Horton, B, Sharma, B, George, RE, Spranger, S, Jaenisch, R et al.. 2020. Cell Stem Cell 26, 579-592.e6.
    doi: 10.1016/j.stem.2020.02.001PMID:32142683
  8. CD36 - the Achilles' heel of Treg cells. Horton, BL, Spranger, S. 2020. Nat Immunol 21, 251-253.
    doi: 10.1038/s41590-020-0601-0PMID:32066948
  9. Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. Nguyen, KB, Spranger, S. 2020. J Cell Biol 219, .
    doi: 10.1083/jcb.201908224PMID:31816057
  10. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). Ascierto, PA, Bifulco, C, Buonaguro, L, Emens, LA, Ferris, RL, Fox, BA, Delgoffe, GM, Galon, J, Gridelli, C, Merlano, M et al.. 2019. J Immunother Cancer 7, 332.
    doi: 10.1186/s40425-019-0798-3PMID:31783779
More Publications



Photo credit: Kelsey Montgomery